Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer, according to a study presented at the 48th Annual Meeting of the Society of Gynecologic Oncology Annual Meeting.1

In the 3-arm GOG-259 trial, 497 women with recurrent or persistent ovarian, fallopian, or primary peritoneal cancer with 3 or more symptoms were randomly assigned to nurse-guided or self-directed WRITE Symptoms interventions or enhanced usual care for 8 weeks. The interventions aimed to help women develop, implement, and refine symptom management plans. Follow-up was at 8 and 12 weeks.

At baseline, the mean age was 59.3 years and 84% of women received chemotherapy and 58.8% had been treated with at least 3 regimens. The mean number of concurrent symptoms was 14.2, with fatigue, constipation, and peripheral neuropathy most commonly identified for intervention.

Continue Reading

During the 12 weeks, symptom burden and quality of life significantly improved in all 3 arms (P <.001 for all). Women who participated in WRITE interventions, but not enhanced usual care, demonstrated improved symptom controllability from baseline through week 12 (P <.001).

The results of this study suggest that though all arms experienced improvement in symptoms and quality of life, only women who participated in the WRITE interventions experienced greater symptom controllability.


1. Donovan HS, Sereika S, Edwards RP, et al. Effects of the WRITE Symptoms interventions on symptoms and quality-of-life outcomes for women with recurrent ovarian cancer. GOG-259: an NRG Oncology/Gynecologic Oncology Group study. Presented at: 48th Annual Meeting of the Society of Gynecologic Oncology; March 12-13, 2017; National Harbor, MD.